Stage 2: 256 Real Stories

256 stories match stage 2. 227 of them mention surgery.

Chance, who was diagnosed with Stage II Breast CancerBreast Cancer

Facing Triple-Negative Breast Cancer: Chance’s Story

Patient Info: Chance, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

As of February 2025, Chance described follow-up after Stage II BRCA1-associated triple-negative breast cancer and stated that she did not currently have cancer, while continuing close surveillance.

The Patient Story
OutcomeCancer-Free / NED
Tracy, who was diagnosed with Stage II Colorectal CancerColorectal Cancer

Stage II Colorectal Cancer: Tracy's Survivor Story

Patient Info: Tracy, Female, 40s | Stage II

As of February 2025, Tracy was in post-treatment survivorship after Stage IIB colorectal cancer treated with 28 days of Xeloda chemoradiation, colostomy surgery in December 2015, and discontinued post-surgery chemotherapy.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Karen, who was diagnosed with Stage II Invasive Lobular CarcinomaBreast Cancer

Stage II HR-Positive Invasive Lobular Carcinoma: Karen's Survivor Story

Patient Info: Karen, Female, 40s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative; grade 2; inherited genetic testing negative

Karen completed double mastectomy, 3 months of chemotherapy and reconstruction. She was doing well on ongoing endocrine and targeted therapy and walking 3–5 miles daily.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing / Survivorship
Stephanie, who was diagnosed with Stage II Non-Small Cell Lung CancerLung Cancer

Stage II ALK Non-Small Cell Lung Cancer: Stephanie's Survivor Story

Patient Info: Stephanie, Female | Stage II

Biomarkers: ALK-rearranged

As of January 2025, Stephanie had clean scans and bloodwork for 3 years after Stage IIB ALK-positive lung adenocarcinoma treated with surgery, 4 rounds of chemotherapy, and ongoing daily targeted therapy.

The Patient Story
OutcomeCancer-Free / NED
Stephanie, who was diagnosed with Stage II Lung AdenocarcinomaLung Cancer

Stage II ALK Lung Adenocarcinoma: Stephanie's Patient Story

Patient Info: Stephanie Williams, Female | Stage II

Biomarkers: ALK-rearranged

Stephanie had clean scans nearly 3 years after diagnosis but remained on daily ALK-targeted therapy to reduce recurrence risk.

The Patient Story
OutcomeCare Ongoing
India, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Breast Cancer: India's Survivor Story

Patient Info: India Robinson, Female, 40s | Stage II

As of January 2025, India had completed Stage II breast cancer treatment and had returned to work, the gym and daily life after robotic lymphatic microsurgery resolved breast lymphedema; the story does not explicitly state NED.

Cleveland Clinic
OutcomeSurvivorship / Surveillance
A patient, who was diagnosed with Stage II Lung AdenocarcinomaLung Cancer

Lung adenocarcinoma mimicking interstitial lung disease: Stage IIB diagnosis after VATS biopsy

Patient Info: Anonymized, Male, 50s | Stage II

Biomarkers: CK7-positive; CK20-positive; TTF-1-positive; CDX2-negative; no EGFR/ALK/ROS1/KRAS molecular results provided

As of January 2025, he had recovered from diagnostic VATS wedge resection/biopsies for reported Stage IIB lung adenocarcinoma and was referred for definitive oncology and pulmonology management.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage II Lung Squamous Cell CarcinomaLung Cancer

Stage IIB squamous cell lung cancer: pathological complete response after chemo-immunotherapy and surgery

Patient Info: Anonymized, Male, 60s | Stage II

Biomarkers: PD-L1 >85%; P40-positive; TTF-1-negative; CEA 1.2 ng/mL; cytokeratin 19 fragments 1.7 ng/mL; pro-gastrin-releasing peptide 54 pg/mL

No recurrence for 1 year and 7 months without further treatment after transbronchoscopic resection, pembrolizumab-based chemoimmunotherapy, pneumonitis management, and sleeve resection showing pathological complete response.

PubMed Central
OutcomeCancer-Free / NED
SI
Colorectal Cancer

Stage II Colorectal Cancer: Casandra's Survivor Story

Patient Info: Casandra | Stage II

Casandra was declared cancer-free in February 2025 and continues to cope with fatigue, fear of recurrence and mistrust after a prolonged diagnostic delay.

Our Cancer Stories
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage II Lung Squamous Cell CarcinomaLung Cancer

Stage IIIA squamous lung cancer: surgery after nivolumab-related complications

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: PD-L1 TPS 99% before treatment; PD-L1 TPS 70% in postoperative hilar lymph node; TPOAb and TgAb normal during thyroiditis workup

As of January 2025, the patient had no recurrence 7 months after neoadjuvant nivolumab/carboplatin/paclitaxel and 5 months after thoracoscopic right upper lobectomy with lymph node dissection.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage II Breast Squamous Cell CarcinomaBreast Cancer

HER2-positive squamous cell breast cancer in complete remission

Patient Info: Anonymized, Female, 40s | Stage II

Biomarkers: HER2-positive squamous cell breast cancer, ER/PR negative, PD-L1 negative

Clinical complete remission and survival beyond 4 years after mastectomy, AC-TH chemotherapy, and HER2-directed maintenance therapy for Stage IIA HER2-positive primary squamous cell breast cancer.

PubMed Central
OutcomeCancer-Free / NED
Lauren, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II Invasive Ductal Carcinoma: Lauren's Survivor Story

Patient Info: Lauren, Female | Stage II

As of November 2024, Lauren had completed surgery, chemotherapy, and 25 rounds of radiation for Stage II invasive ductal breast cancer and was moving into survivorship.

The Patient Story
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage II Lung AdenocarcinomaLung Cancer

Recurrent Lung Adenocarcinoma Complicated by a Tracheopericardial Fistula

Patient Info: Anonymized, male, 70+ | Stage II

Biomarkers: No gene mutations identified on postoperative testing

He died during the June 2024 admission, about 7½ years after his November 2016 lung-cancer diagnosis, after massive hemoptysis occurred in the setting of a tracheopericardial fistula and recurrent cancer.

PubMed Central
OutcomeIn Memory
Italia, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Triple-Negative Breast Cancer: Italia's Survivor Story

Patient Info: Italia Russell, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA mutation

As of October 2024, Italia had no evidence of disease after Stage II triple-negative breast cancer responded to chemotherapy, the tumor was gone by double mastectomy, and she was completing immunotherapy with 3 infusions left.

Cleveland Clinic
OutcomeCancer-Free / NED
Maddee, who was diagnosed with Stage II Colorectal CancerColorectal Cancer

Stage II Colorectal Cancer: Maddee's Survivor Story

Patient Info: Maddee Moore, Female, Under 40 | Stage II

Biomarkers: Lynch syndrome

As of October 2024, Maddee had no reported recurrence after surgery for Stage II colon cancer and remained in close surveillance because of Lynch syndrome.

The Patient Story
OutcomeCancer-Free / NED
Maddee, who was diagnosed with Stage II Colorectal CancerColorectal Cancer

Maddee: Stage II Colorectal Cancer

Patient Info: Maddee, Female | Stage II

Biomarkers: Lynch syndrome

As of October 2024, Maddee was in surveillance after surgery for Stage II Lynch syndrome-associated colon cancer, with about 1 foot of colon and 40 lymph nodes removed and no chemotherapy given.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage II Invasive Lobular CarcinomaBreast Cancer

Hormone receptor-positive invasive lobular carcinoma treated with neoadjuvant chemotherapy

Patient Info: Anonymized, Female, 50s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative; Ki-67 20%

Three-month follow-up showed the biopsy-related pseudoaneurysm had thrombosed and regressed, clearing the way for planned neoadjuvant chemotherapy and surgery; cancer response after planned treatment was not yet available.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

ER-positive breast cancer: mastectomy after hormone therapy

Patient Info: Anonymized, Female, 50s | Stage II

Biomarkers: Breast cancer was ER+ and HER2-low/negative. PR changed from positive on biopsy to negative on final pathology; HNA-1 antibody found for neutropenia.

Stage IIA ER-positive invasive ductal breast cancer had no recurrence 3 years after endocrine therapy and total mastectomy with sentinel lymph node biopsy; autoimmune neutropenia was monitored rather than directly treated.

PubMed Central
OutcomeCancer-Free / NED
Att, who was diagnosed with Stage II Lung CancerLung Cancer

Stage II Lung Cancer: Att's Patient Story

Patient Info: Att Callahan, Female, 70+ | Stage II

As of July 2024, Att was receiving monthly post-surgery immunotherapy and scans every other month after clinical-trial chemoimmunotherapy and lobectomy, with doctors believing they had removed all visible cancer.

MD Anderson
OutcomeCare Ongoing
Kelsey, who was diagnosed with Stage II Breast CancerBreast Cancer

Finding A Lump To BREAST CANCER!

Patient Info: Kelsey Harrison, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of July 2024, Kelsey had completed chemotherapy, double mastectomy with axillary lymph-node removal, and radiation, and was continuing tamoxifen plus Lupron ovarian suppression with additional planned systemic therapy.

The Patient Story
OutcomeCare Ongoing
A patient, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Breast Cancer Treatment Complicated by Scleroderma-Like Skin Changes

Patient Info: Anonymized, female, 50s | Stage II

Biomarkers: ER low-positive; PR-negative; HER2-negative

Her cancer remained stable during combination treatment. After morphea-like skin changes developed during therapy, treatment was modified and the skin condition improved 6 months after docetaxel was stopped.

PubMed Central
OutcomeCare Ongoing